期刊文献+

RECK在非小细胞肺癌中的表达及意义

Expression of RECK in non-small cell lung cancer and its clinical significance
暂未订购
导出
摘要 目的:研究RECK在肺癌组织和非癌组织中的表达,探讨其在肺癌浸润和转移中的作用。方法:临床及病理资料完整的非小细胞肺癌组织50例,及20例非癌肺组织,采用免疫组化SP法检测RECK的表达情况。结果:RECK在肺癌组织中的表达阳性率(20%)明显低于其在非癌组织中的表达阳性率(90%),两者相比有明显的统计学差异(P<0.001);在肺癌组织中,RECK的表达与患者的年龄、性别、是否吸烟及吸烟量、病理类型、分化程度无明显关系,与是否有淋巴结转移(P=0.001)及TNM分期有关(P=0.034)。与有淋巴结转移和TNM分期晚期(Ⅲ、Ⅳ期)的患者相比,无淋巴结转移和TNM分期早期(Ⅰ、Ⅱ期)的患者RECK的表达水平明显高。结论:RECK在肺癌组织中低表达,与肺癌的侵袭和转移密切相关。 Objective:To study the expression of reversion-inducing-cysterine-rich protein with kazal motif(RECK) in non-small cell lung cancer(NSCLC) and its effect on the invasion and metastasis of NSCLC.Methods: SP immunohistochemical method was used to detect the protein expression of RECK in 50 cases of NSCLC and 20 cases of non-cancerous lung tissues.Results: The positive expression rate of RECK in the case of NSCLC was 20%,which was lower than that in non-cancerous lung tissues(90%),and the difference was statistically significant(P0.001).There were significant correlations between the RECK expression and cancer lymph node invasion(P=0.001)and TNM staging(P=0.034),rather than age,sexuality,smoking,pathological types,or the degrees of differentiation.Compared with patients with lymph node invasion and advanced stage of TNM staging(Ⅲ,Ⅳ stage),the expression rate of RECK was significantly increased in the cases with no lymph node invasion and the earlier period of TNM staging(Ⅰ,Ⅱ stage).Conclusion: The expression of RECK in NSCLC is lower,and is closely correlated to the invasion and metastasis.
出处 《现代肿瘤医学》 CAS 2012年第10期2067-2070,共4页 Journal of Modern Oncology
基金 陕西省科技攻关项目(编号:2006K08-G15)
关键词 RECK 非小细胞肺癌 免疫组织化学 RECK non-small cell lung cancer immunohistochemistry
  • 相关文献

参考文献1

二级参考文献15

  • 1李杰茹,齐凤英,李丽.MMP-2在食管癌中的表达及其与血管生成的相关性[J].中华肿瘤杂志,2005,27(2):96-98. 被引量:14
  • 2程瑜,董蒨,孙立荣,杨传民,江布先.基质金属蛋白酶及其抑制因子与神经母细胞瘤侵袭转移的关系[J].中华肿瘤杂志,2005,27(3):164-166. 被引量:14
  • 3Rydlova M,Holubec L Jr,Ludvikova M Jr,et al.Biological activity and clinical implications of the matrix metalloproteinases.Anticancer Res,2008,28:1389-1397.
  • 4Deryugina EI,Quigley JP.Matrix metalloproteinases and tumor metastasis.Cancer Metastasis Rev,2006,25:9-34.
  • 5Maskos K,Bode W.Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.Mol Biotechnol,2003,25:241-266.
  • 6No(e)l A,Jost M,Maquoi E.Matrix metalloproteinases at cancer tumor-host interface.Semin Cell Dev Biol,2008,19:52-60.
  • 7Yan C,Boyd DD.Regulation of matrix metalloproteinase gene expression.J Cell Physiol,2007,211:19-26.
  • 8Alakus H,Grass G,Henneeken JK,et al.Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.Histol Histopathol,2008,23:917-923.
  • 9Pritchard SC,Nicolson MC,Lloret C,et al.Expression of matrix metalloproteinases 1,2,9 and their tissue inhibitors in stage Ⅱ non-small cell lung cancer:implications for MMP inhibition therapy.Oncol Rep,2001,8:421-424.
  • 10Takahashi C,Sheng Z,Horan TP,et al.Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.Proc Natl Acad Sci U S A,1998,95:13221-13226.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部